Rubella diagnostic testing market outlook (2026–2030) driven by growth factors

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Rubella Diagnostic Testing Market During The Forecast Period?

The rubella diagnostic testing market has experienced significant expansion in recent years. It is projected to increase from $1.39 billion in 2025 to $1.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. This historical growth can be attributed to the broadening of routine viral screening programs, heightened awareness regarding congenital rubella syndrome, the availability of serological testing kits, the expansion of diagnostic laboratory networks, and the adoption of immunoassay technologies.

The rubella diagnostic testing market is anticipated to experience substantial expansion over the coming years. By 2030, its valuation is projected to reach $1.89 billion, advancing at a compound annual growth rate (CAGR) of 6.4%. This projected growth during the forecast period stems from factors such as heightened investments in sophisticated diagnostic platforms, an increased emphasis on maternal health screening, the broadened scope of automated laboratory testing, wider uptake of point-of-care diagnostics, and the reinforcement of infectious disease surveillance systems. Key trends during this period are expected to encompass the growing embrace of molecular diagnostic techniques, an increased application of PCR-based rubella testing, escalating demand for prenatal screening, the proliferation of high-sensitivity immunoassays, and a heightened emphasis on detecting diseases early.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19177&type=smp

What Key Drivers Are Fueling The Growth Of The Rubella Diagnostic Testing Market?

The increasing incidence of viral infections is projected to stimulate the expansion of the rubella diagnostic testing market in the future. Viral infections are diseases caused by viruses, which are microscopic infectious agents capable of reproducing only within the living cells of an organism. The escalation in viral infection cases can be attributed to heightened global travel, which aids in the cross-border spread of viruses, and climate change, which modifies vector habitats and expands the geographical reach of disease-carrying organisms. Rubella diagnostic testing plays a crucial role in the early detection and management of rubella infections, helping to avert complications, especially in expectant mothers, and contributing to outbreak containment to mitigate virus transmission. For instance, in December 2023, data from the National Health Service, a UK-based government department, showed that daily hospital admissions for flu averaged 234, indicating a 53% rise from the preceding week, while norovirus hospital cases climbed by 15% to an average of 406 daily, marking a 28% increase compared to the same week last year. Thus, the growing number of viral infections is propelling the growth of the rubella diagnostic testing market.

What Are The Different Segment Types In The Rubella Diagnostic Testing Market Segment Breakdown?

The rubella diagnostic testing market covered in this report is segmented –

1) By Diagnostic Technique: Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (Ria), Fluorescent Immunoassay (FIA), Other Diagnostic Techniques

2) By Age Group: Neonates, Teenagers, Adults

3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Public Health Laboratories, Other End Users

Subsegments:

1) By Latex Agglutination: Qualitative Latex Agglutination Tests, Quantitative Latex Agglutination Tests, Rapid Latex Agglutination Kits

2) By Enzyme Immunoassay (EIA): Direct EIA, Indirect EIA, Sandwich EIA, Competitive EIA

3) By Radioimmunoassay (RIA): Standard RIA, Modified RIA, Single-Antibody RIA

4) By Fluorescent Immunoassay (FIA): Direct FIA, Indirect FIA, Sandwich FIA

5) By Other Diagnostic Techniques: Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAAT), Microplate-Based Assays, Western Blotting

What Trends Are Influencing The Rubella Diagnostic Testing Market?

Companies operating within the rubella diagnostic testing market are prioritizing the creation of advanced solutions, such as the rubella virus vaccine, to enhance diagnostic precision and strengthen preventive measures. The rubella virus vaccine offers protection against rubella, frequently administered as part of combination vaccines like MMR or MMRV to avert the illness and related issues. For example, in March 2023, Merck & Co., Inc., a US-based pharmaceutical firm, secured FDA approval for the intramuscular (IM) delivery of its M-M-R II vaccine, which is crucial for safeguarding against rubella, alongside measles and mumps. This approval enables healthcare providers to administer the rubella vaccine via the IM method, making it consistent with other common pediatric immunizations. Rubella immunization is vital for averting outbreaks and protecting against the serious complications the virus can induce, particularly in expecting mothers.

Who Are The Well-Known Companies In The Rubella Diagnostic Testing Market?

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH

Get The Full Rubella Diagnostic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report

Which Region Is The Top Contributor To The Rubella Diagnostic Testing Market By Share?

North America was the largest region in the rubella diagnostic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rubella Diagnostic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rubella-diagnostic-testing-global-market-report

Browse Through More Reports Similar to the Global Rubella Diagnostic Testing Market 2026, By The Business Research Company

Gastrointestinal Pathogen Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-pathogen-testing-global-market-report

Clinical Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Hospital Acquired Infections Testing Kits Market Report

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795